C Whalen, CR Horsburgh, D Hom, C Lahart, M Simberkoff and J Ellner
Department of Medicine, Cleveland Veterans Affairs Medical Center, Ohio.

To determine the effect of active tuberculosis on survival and the incidence of opportunistic infections in HIV-infected patients, we performed a retrospective cohort study at four U.S. medical centers to compare the survival and incidence rate of opportunistic infections in 106 HIV-infected patients with active tuberculosis (cases) with that of 106 HIV-infected patients without tuberculosis (control subjects) but with a similar level of immunosuppression (measured by the absolute CD4+ lymphocyte count) as the cases. Cases and control subjects were similar with regard to age, sex, race, previous opportunistic infection, and use of antiretroviral therapy, but they were more likely than control subjects to have a history of intravenous drug use (49 versus 19%). The mean CD4+ counts were similar for cases and control subjects (154 versus 153 cells/microliters, respectively). The incidence rate of new AIDS-defining opportunistic infections in cases was 4.0 infections per 100 person-months compared with 2.8 infections per 100 person-months in control subjects for an incidence rate ratio (RR) of 1.42 (95% confidence interval: 0.94-2.11). Cases also had a shorter overall survival than did controls subjects (p = 0.001). Active tuberculosis was associated with an increased risk for death (odds ratio = 2.17), even when controlling for age, intravenous drug use, previous opportunistic infection, baseline CD4+ count, and antiretroviral therapy. Although active tuberculosis may be an independent marker of advanced immunosuppression in HIV-infected patients, it may also act as a cofactor to accelerate the clinical course of HIV infection.

This article has been cited by other articles:

				I. Komuro, T. Sunazuka, K. S. Akagawa, Y. Yokota, A. Iwamoto, and S. Omura Erythromycin derivatives inhibit HIV-1 replication in macrophages through modulation of MAPK activity to induce small isoforms of C/EBP{beta} PNAS, August 26, 2008; 105(34): 12509 - 12514. [Abstract] [Full Text] [PDF]

				H Lopez-Gatell, S. Cole, N. Hessol, A. French, R. Greenblatt, S Landesman, S Preston-Martin, and K Anastos Effect of Tuberculosis on the Survival of Women Infected with Human Immunodeficiency Virus Am. J. Epidemiol., May 15, 2007; 165(10): 1134 - 1142. [Abstract] [Full Text] [PDF]

				H. J Zar, M. F Cotton, S. Strauss, J. Karpakis, G. Hussey, H S. Schaaf, H. Rabie, and C. J Lombard Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial BMJ, January 20, 2007; 334(7585): 136 - 136. [Abstract] [Full Text] [PDF]

				D. Lin, M J. Tucker, and M. J Rieder Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection Ann. Pharmacother., September 1, 2006; 40(9): 1594 - 1601. [Abstract] [Full Text] [PDF]

				M. BROWN, G. MIIRO, P. NKURUNZIZA, C. WATERA, M. A. QUIGLEY, D. W. DUNNE, J. A. G. WHITWORTH, and A. M. ELLIOTT SCHISTOSOMA MANSONI, NEMATODE INFECTIONS, AND PROGRESSION TO ACTIVE TUBERCULOSIS AMONG HIV-1-INFECTED UGANDANS. Am J Trop Med Hyg, May 1, 2006; 74(5): 819 - 825. [Abstract] [Full Text] [PDF]

				D.-J. Thomas Mycobacterial Diseases in HIV-Positive Patients Journal of Pharmacy Practice, February 1, 2006; 19(1): 10 - 16. [Abstract] [PDF]

				E. C. JONES-LOPEZ, A. OKWERA, H. MAYANJA-KIZZA, J. J. ELLNER, R. D. MUGERWA, C. C. WHALEN, and THE UGANDA-CASE WESTERN RESERVE UNIVERSITY RESEARC DELAYED-TYPE HYPERSENSITIVITY SKIN TEST REACTIVITY AND SURVIVAL IN HIV-INFECTED PATIENTS IN UGANDA: SHOULD ANERGY BE A CRITERION TO START ANTIRETROVIRAL THERAPY IN LOW-INCOME COUNTRIES? Am J Trop Med Hyg, January 1, 2006; 74(1): 154 - 161. [Abstract] [Full Text] [PDF]

				H. M. Kizza, B. Rodriguez, M. Quinones-Mateu, M. Mirza, H. Aung, B. Yen-Lieberman, C. Starkey, L. Horter, P. Peters, J. Baseke, et al. Persistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects Clin. Vaccine Immunol., November 1, 2005; 12(11): 1298 - 1304. [Abstract] [Full Text] [PDF]

				L H Calabrese, N Zein, and D Vassilopoulos Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection Ann Rheum Dis, November 1, 2004; 63(suppl_2): ii18 - ii24. [Abstract] [Full Text] [PDF]

				P. de Colombani, N. Banatvala, R. Zaleskis, and D. Maher European framework to decrease the burden of TB/HIV Eur. Respir. J., September 1, 2004; 24(3): 493 - 501. [Abstract] [Full Text] [PDF]

				J. A. Gold, Y. Hoshino, N. Tanaka, W. N. Rom, B. Raju, R. Condos, and M. D. Weiden Surfactant Protein A Modulates the Inflammatory Response in Macrophages during Tuberculosis Infect. Immun., February 1, 2004; 72(2): 645 - 650. [Abstract] [Full Text] [PDF]

				S. Ranjbar, N. Ly, S. Thim, J.-M. Reynes, and A. E. Goldfeld Mycobacterium tuberculosis Recall Antigens Suppress HIV-1 Replication in Anergic Donor Cells via CD8+ T Cell Expansion and Increased IL-10 Levels J. Immunol., February 1, 2004; 172(3): 1953 - 1959. [Abstract] [Full Text] [PDF]

				A. Bafica, C. A. Scanga, M. L. Schito, S. Hieny, and A. Sher Cutting Edge: In Vivo Induction of Integrated HIV-1 Expression by Mycobacteria Is Critically Dependent on Toll-Like Receptor 2 J. Immunol., August 1, 2003; 171(3): 1123 - 1127. [Abstract] [Full Text] [PDF]

				P. Cahn, H. Perez, G. Ben, and C. Ochoa Tuberculosis and HIV: A Partnership Against the Most Vulnerable J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2003; 2(3): 106 - 123. [Abstract] [PDF]

				O. Equils, M. L. Schito, H. Karahashi, Z. Madak, A. Yarali, K. S. Michelsen, A. Sher, and M. Arditi Toll-Like Receptor 2 (TLR2) and TLR9 Signaling Results in HIV-Long Terminal Repeat Trans-Activation and HIV Replication in HIV-1 Transgenic Mouse Spleen Cells: Implications of Simultaneous Activation of TLRs on HIV Replication J. Immunol., May 15, 2003; 170(10): 5159 - 5164. [Abstract] [Full Text] [PDF]

				R. Condos, B. Raju, A. Canova, B.-Y. Zhao, M. Weiden, W. N. Rom, and R. Pine Recombinant Gamma Interferon Stimulates Signal Transduction and Gene Expression in Alveolar Macrophages In Vitro and in Tuberculosis Patients Infect. Immun., April 1, 2003; 71(4): 2058 - 2064. [Abstract] [Full Text]

				Y. Hoshino, K. Nakata, S. Hoshino, Y. Honda, D. B. Tse, T. Shioda, W. N. Rom, and M. Weiden Maximal HIV-1 Replication in Alveolar Macrophages during Tuberculosis Requires both Lymphocyte Contact and Cytokines J. Exp. Med., February 19, 2002; 195(4): 495 - 505. [Abstract] [Full Text] [PDF]

				K. R. Collins, M. E. Quinones-Mateu, M. Wu, H. Luzze, J. L. Johnson, C. Hirsch, Z. Toossi, and E. J. Arts Human Immunodeficiency Virus Type 1 (HIV-1) Quasispecies at the Sites of Mycobacterium tuberculosis Infection Contribute to Systemic HIV-1 Heterogeneity J. Virol., February 15, 2002; 76(4): 1697 - 1706. [Abstract] [Full Text] [PDF]

				Tuberculosis and HIV AIDS Clinical Care, February 1, 2002; 2002(201): 6 - 6. [Full Text]

				C. Gioia, C. Agrati, R. Casetti, C. Cairo, G. Borsellino, L. Battistini, G. Mancino, D. Goletti, V. Colizzi, L. P. Pucillo, et al. Lack of CD27-CD45RA-V{gamma}9V{delta}2+ T Cell Effectors in Immunocompromised Hosts and During Active Pulmonary Tuberculosis J. Immunol., February 1, 2002; 168(3): 1484 - 1489. [Abstract] [Full Text] [PDF]

				S. D. Lawn, S. T. Butera, and T. M. Folks Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection Clin. Microbiol. Rev., October 1, 2001; 14(4): 753 - 777. [Abstract] [Full Text] [PDF]

				C. T. Tiemessen, S. Shalekoff, S. Meddows-Taylor, and D. J. Martin Antituberculosis Treatment: Increasing Evidence for Drug Effects on Innate Cellular Immunity Clin. Vaccine Immunol., July 1, 2001; 8(4): 686 - 689. [Full Text] [PDF]

				M. Zaitseva, S. Lee, C. Lapham, R. Taffs, L. King, T. Romantseva, J. Manischewitz, and H. Golding Interferon gamma and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency virus type 1 infection Blood, November 1, 2000; 96(9): 3109 - 3117. [Abstract] [Full Text] [PDF]

				A. Zumla, P. Malon, J. Henderson, and J. M Grange Impact of HIV infection on tuberculosis Postgrad. Med. J., May 1, 2000; 76(895): 259 - 268. [Abstract] [Full Text]

				F. Gordin, R. E. Chaisson, J. P. Matts, C. Miller, M. d. L. Garcia, R. Hafner, J. L. Valdespino, J. Coberly, M. Schechter, A. J. Klukowicz, et al. Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected Persons: An International Randomized Trial JAMA, March 15, 2000; 283(11): 1445 - 1450. [Abstract] [Full Text] [PDF]

				T. M. Doherty, C. Chougnet, M. Schito, B. K. Patterson, C. Fox, G. M. Shearer, G. Englund, and A. Sher Infection of HIV-1 Transgenic Mice with Mycobacterium avium Induces the Expression of Infectious Virus Selectively from a Mac-1-Positive Host Cell Population J. Immunol., August 1, 1999; 163(3): 1506 - 1515. [Abstract] [Full Text] [PDF]

				J. M. FitzGerald and S. Houston Tuberculosis: 8. The disease in association with HIV infection Can. Med. Assoc. J., July 1, 1999; 161(1): 47 - 51. [Abstract] [Full Text] [PDF]

				D. C. SNYDER, E. A. PAZ, J. C. MOHLE-BOETANI, R. FALLSTAD, R. L. BLACK, and D. P. CHIN Tuberculosis Prevention in Methadone Maintenance Clinics . Effectiveness and Cost-Effectiveness Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 178 - 185. [Abstract] [Full Text]

				C MAYAUD and J CADRANEL Tuberculosis in AIDS: past or new problems? Thorax, July 1, 1999; 54(7): 567 - 571. [Full Text]

				S. Meddows-Taylor, D. J. Martin, and C. T. Tiemessen Impaired Interleukin-8-Induced Degranulation of Polymorphonuclear Neutrophils from Human Immunodeficiency Virus Type 1-Infected Individuals Clin. Vaccine Immunol., May 1, 1999; 6(3): 345 - 351. [Abstract] [Full Text] [PDF]

				P. F. BARNES, Z. YANG, J. M. POGODA, S. PRESTON-MARTIN, B. E. JONES, M. OTAYA, L. KNOWLES, S. HARVEY, K. D. EISENACH, and M. DONALD CAVE Foci of Tuberculosis Transmission in Central Los Angeles Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1081 - 1086. [Abstract] [Full Text] [PDF]

				S. Meddows-Taylor, D. J. Martin, and C. T. Tiemessen Dysregulated Production of Interleukin-8 in Individuals Infected with Human Immunodeficiency Virus Type 1 and Mycobacterium tuberculosis Infect. Immun., March 1, 1999; 67(3): 1251 - 1260. [Abstract] [Full Text] [PDF]

				P. R. Skolnik and E. J. Mark Case 5-1999- A 37-Year-Old Man with Fever and Diffuse Lymphadenopathy N. Engl. J. Med., February 18, 1999; 340(7): 545 - 554. [Full Text] [PDF]

				D. Zhou, Y. Shen, L. Chalifoux, D. Lee-Parritz, M. Simon, P. K. Sehgal, L. Zheng, M. Halloran, and Z. W. Chen Mycobacterium bovis Bacille Calmette-Guerin Enhances Pathogenicity of Simian Immunodeficiency Virus Infection and Accelerates Progression to AIDS in Macaques: A Role of Persistent T cell Activation in AIDS Pathogenesis J. Immunol., February 15, 1999; 162(4): 2204 - 2216. [Abstract] [Full Text] [PDF]

				D. V. Havlir and P. F. Barnes Tuberculosis in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373. [Full Text] [PDF]

				E. L. CORBETT, G. J. CHURCHYARD, T. CLAYTON, P. HERSELMAN, B. WILLIAMS, R. HAYES, D. MULDER, and K. M. DE COCK Risk Factors for Pulmonary Mycobacterial Disease in South African Gold Miners . A Case-Control Study Am. J. Respir. Crit. Care Med., January 1, 1999; 159(1): 94 - 99. [Abstract] [Full Text]

				H. Sawert, E. Girardi, G. Antonucci, M. C. Raviglione, P. Viale, G. Ippolito, and for the Gruppo Italiano di Studio Tubercolosi e AI Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count Arch Intern Med, October 26, 1998; 158(19): 2112 - 2121. [Abstract] [Full Text] [PDF]

				S. M. Wahl, T. Greenwell-Wild, G. Peng, H. Hale-Donze, T. M. Doherty, D. Mizel, and J. M. Orenstein Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression PNAS, October 13, 1998; 95(21): 12574 - 12579. [Abstract] [Full Text] [PDF]

				Y. Honda, L. Rogers, K. Nakata, B.-Y. Zhao, R. Pine, Y. Nakai, K. Kurosu, W. N. Rom, and M. Weiden Type I Interferon Induces Inhibitory 16-kD CCAAT/ Enhancer Binding Protein (C/EBP){beta}, Repressing the HIV-1 Long Terminal Repeat in Macrophages: Pulmonary Tuberculosis Alters C/EBP Expression, Enhancing HIV-1 Replication J. Exp. Med., October 5, 1998; 188(7): 1255 - 1265. [Abstract] [Full Text] [PDF]

				S. Shalekoff, C. T. Tiemessen, C. M. Gray, and D. J. Martin Depressed Phagocytosis and Oxidative Burst in Polymorphonuclear Leukocytes from Individuals with Pulmonary Tuberculosis with or without Human Immunodeficiency Virus Type 1 Infection Clin. Vaccine Immunol., January 1, 1998; 5(1): 41 - 44. [Abstract] [Full Text]

				S. Moreno, P. Miralles, M. D. Diaz, J. Baraia, B. Padilla, J. Berenguer, and J. C. Alberdi Isoniazid Preventive Therapy in Human Immunodeficiency Virus-Infected Persons: Long-term Effect on Development of Tuberculosis and Survival Arch Intern Med, August 11, 1997; 157(15): 1729 - 1734. [Abstract] [PDF]

				J. M. Orenstein, C. Fox, and S. M. Wahl Macrophages as a Source of HIV During Opportunistic Infections Science, June 20, 1997; 276(5320): 1857 - 1861. [Abstract] [Full Text]

				Treating Concurrent HIV and TB: A Clinical Alert from the CDC AIDS Clinical Care, December 1, 1996; 1996(1201): 1 - 1. [Full Text]

				H. V. Fineberg Social Vulnerability and Death by Infection N. Engl. J. Med., March 28, 1996; 334(13): 858 - 860. [Full Text]

				T. V Perneger, P. Sudre, J. D Lundgren, and B. Hirschel Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years BMJ, December 2, 1995; 311(7018): 1468 - 1471. [Abstract] [Full Text]